The relatively high expression of GPR120 in adipose tissue, macrophages, and intestine has resulted, to date, in a focus on its contribution to insulin signaling, obesity, and anti-inflammatory responses and, on the basis of these, the potential for GPR120 agonists to regulate glucose homeostasis and act as potential medicines to treat type II diabetes (7). This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.